Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Genetic Abnormalities
Ariol 2.0 launched as next-generation cellular imaging system
September 5th, 2004
Applied Imaging Corp. (AICX) announced the release of Ariol 2.0, the latest generation of its Ariol imaging analysis system. Ariol 2.0 combines screening for genetic abnormalities and protein expression in a single instrumentation platform. This new release provides clinical laboratories with significant additional functionality, including a suite of advanced image analysis technologies for cancer testing and drug discovery. These new molecular analysis applications extend the tools available to a wide range of genetics and pathology laboratories, biotech and pharmaceutical companies and research institutions. These new applications are released for...
Source: Medical Letter on the CDC & FDA (2004-09-05)
|
